China Regenerative Medicine 08158 announced its mid-term performance for 2024, with revenue of HKD 59.785 million, a YoY decrease...
According to the Zhongtong Finance APP, China Regenerative Medicine 08158 announced its mid-term performance for 2024, with revenue of HKD 59.785 million, a YoY decrease of 19.44%; net profit of HKD 16.828 million, a YoY increase of 31.86%; and earnings per share of 5.53 HK cents.
The announcement stated that the overall decrease in revenue was mainly due to retaliatory consumer behavior by mainland Chinese customers in 2023 after the lifting of epidemic prevention measures, which was not the case in 2024.